Regeneron Pharmaceuticals Receives Consensus Recommendation of “Buy” from Brokerages (NASDAQ:REGN)
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) have earned a consensus rating of “Buy” from the twenty-three analysts that are covering the company, Analyst RN reports. Seven equities research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $346.21.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 1.62% during mid-day trading on Thursday, hitting $295.70. 172,292 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 52 week low of $206.30 and a 52 week high of $352.49. The stock has a 50-day moving average of $293.2 and a 200-day moving average of $296.3. The company has a market cap of $29.188 billion and a price-to-earnings ratio of 83.43.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings data on Thursday, May 8th. The company reported $0.58 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.94 by $0.36. The company had revenue of $626.00 million for the quarter, compared to the consensus estimate of $609.04 million. During the same quarter in the prior year, the company posted $1.78 earnings per share. The company’s quarterly revenue was up 42.3% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $9.83 EPS for the current fiscal year.
REGN has been the subject of a number of recent research reports. Analysts at BMO Capital Markets cut their price target on shares of Regeneron Pharmaceuticals from $331.00 to $283.00 in a research note on Friday, May 9th. Separately, analysts at Zacks reiterated an “outperform” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 9th. They now have a $337.00 price target on the stock. Finally, analysts at Cowen and Company raised their price target on shares of Regeneron Pharmaceuticals from $276.00 to $285.00 in a research note on Friday, May 9th. They now have a “market perform” rating on the stock.
In other Regeneron Pharmaceuticals news, major shareholder Sanofi purchased 190,751 shares of the company’s stock in a transaction that occurred on Monday, May 19th. The stock was purchased at an average cost of $300.04 per share, for a total transaction of $57,232,930.04. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.